icon-folder.gif   Conference Reports for NATAP  
 
  17th International Workshop
on Clinical Pharmacology of
HIV and Hepatitis Therapy
June 8-10, 2016, Washington DC
Back grey_arrow_rt.gif
 
 
 
No Clinically Significant Interaction of MK-8408 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate
 
 
  Reported by Jules Levin
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy Washington, DC June 8-10, 2016
 
Wei Gao; Jennifer Talaty; Leticia Arrington; Graig Garrett; William L. Marshall; Nancy Kim*; Eugene E. Marcantonio *Corresponding author
Merck & Co., Inc., Kenilworth, NJ, USA

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6